![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLPPR2 |
Gene summary for PLPPR2 |
![]() |
Gene information | Species | Human | Gene symbol | PLPPR2 | Gene ID | 64748 |
Gene name | phospholipid phosphatase related 2 | |
Gene Alias | LPPR2 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q96GM1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64748 | PLPPR2 | LZE4T | Human | Esophagus | ESCC | 7.64e-08 | 1.97e-01 | 0.0811 |
64748 | PLPPR2 | LZE24T | Human | Esophagus | ESCC | 1.21e-14 | 3.47e-01 | 0.0596 |
64748 | PLPPR2 | P8T-E | Human | Esophagus | ESCC | 6.37e-10 | 1.16e-01 | 0.0889 |
64748 | PLPPR2 | P9T-E | Human | Esophagus | ESCC | 1.61e-03 | 7.55e-02 | 0.1131 |
64748 | PLPPR2 | P10T-E | Human | Esophagus | ESCC | 1.58e-08 | 2.30e-01 | 0.116 |
64748 | PLPPR2 | P11T-E | Human | Esophagus | ESCC | 1.24e-15 | 5.25e-01 | 0.1426 |
64748 | PLPPR2 | P12T-E | Human | Esophagus | ESCC | 1.14e-07 | 2.12e-01 | 0.1122 |
64748 | PLPPR2 | P15T-E | Human | Esophagus | ESCC | 1.63e-05 | 1.32e-01 | 0.1149 |
64748 | PLPPR2 | P16T-E | Human | Esophagus | ESCC | 6.52e-11 | 2.11e-01 | 0.1153 |
64748 | PLPPR2 | P17T-E | Human | Esophagus | ESCC | 1.78e-09 | 3.18e-01 | 0.1278 |
64748 | PLPPR2 | P19T-E | Human | Esophagus | ESCC | 2.63e-06 | 4.65e-01 | 0.1662 |
64748 | PLPPR2 | P20T-E | Human | Esophagus | ESCC | 1.84e-02 | 3.61e-02 | 0.1124 |
64748 | PLPPR2 | P21T-E | Human | Esophagus | ESCC | 5.39e-20 | 3.96e-01 | 0.1617 |
64748 | PLPPR2 | P22T-E | Human | Esophagus | ESCC | 3.36e-06 | 1.44e-01 | 0.1236 |
64748 | PLPPR2 | P23T-E | Human | Esophagus | ESCC | 5.65e-16 | 3.94e-01 | 0.108 |
64748 | PLPPR2 | P24T-E | Human | Esophagus | ESCC | 8.25e-06 | 1.63e-01 | 0.1287 |
64748 | PLPPR2 | P26T-E | Human | Esophagus | ESCC | 3.65e-16 | 2.93e-01 | 0.1276 |
64748 | PLPPR2 | P27T-E | Human | Esophagus | ESCC | 2.92e-10 | 1.49e-01 | 0.1055 |
64748 | PLPPR2 | P28T-E | Human | Esophagus | ESCC | 1.07e-11 | 1.38e-01 | 0.1149 |
64748 | PLPPR2 | P30T-E | Human | Esophagus | ESCC | 4.59e-14 | 6.15e-01 | 0.137 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00302586 | Esophagus | ESCC | lipid modification | 116/8552 | 212/18723 | 4.90e-03 | 1.89e-02 | 116 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLPPR2 | SNV | Missense_Mutation | c.1234C>T | p.Arg412Trp | p.R412W | Q96GM1 | protein_coding | tolerated_low_confidence(0.29) | benign(0.003) | TCGA-A2-A1G1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLPPR2 | SNV | Missense_Mutation | c.431T>C | p.Leu144Pro | p.L144P | Q96GM1 | protein_coding | deleterious(0.03) | benign(0.332) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PLPPR2 | SNV | Missense_Mutation | c.873N>C | p.Lys291Asn | p.K291N | Q96GM1 | protein_coding | deleterious(0.04) | probably_damaging(0.92) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLPPR2 | insertion | Nonsense_Mutation | novel | c.591_592insATGGAGAAGGGTGTGGACTCTGTGTGACCTTGGGCCAATCCCT | p.Tyr198MetfsTer9 | p.Y198Mfs*9 | Q96GM1 | protein_coding | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
PLPPR2 | SNV | Missense_Mutation | c.221N>T | p.Pro74Leu | p.P74L | Q96GM1 | protein_coding | tolerated(0.46) | benign(0.089) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLPPR2 | SNV | Missense_Mutation | rs556549966 | c.202N>T | p.Arg68Cys | p.R68C | Q96GM1 | protein_coding | tolerated(0.17) | possibly_damaging(0.781) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PLPPR2 | SNV | Missense_Mutation | c.1234N>T | p.Arg412Trp | p.R412W | Q96GM1 | protein_coding | tolerated_low_confidence(0.29) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLPPR2 | SNV | Missense_Mutation | novel | c.1207A>G | p.Ser403Gly | p.S403G | Q96GM1 | protein_coding | tolerated_low_confidence(0.27) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLPPR2 | SNV | Missense_Mutation | novel | c.296N>A | p.Arg99Gln | p.R99Q | Q96GM1 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLPPR2 | SNV | Missense_Mutation | novel | c.449N>T | p.Ser150Phe | p.S150F | Q96GM1 | protein_coding | deleterious(0.02) | benign(0.282) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |